Antheia Announces $73M Series B to Commercialize Synthetic Biology Platform for Essential Medicines

MENLO PARK, Calif., June 30, 2021 /PRNewswire/ -- Antheia, a synthetic biology company enabling next-generation plant-inspired medicines, announced today that it has raised $73M in Series B financing. The oversubscribed round was led by Viking Global Investors and included participation from Sherpalo Ventures and Hillspire. The funds will support Antheia as it brings its first pharmaceutical compound to market and scales up the production of a number of critical active pharmaceutical ingredients (APIs) and key starting materials (KSMs).


Read the article at PR Newsire.

0 comments